5
2.
Shotwell, J. B.; Baskaran, S.; Chong, P.; Creech, K. L.; Crosby, R.
M.; Dickson, H.; Fang, J.; Garrido, D.; Mathis, A.; Maung, J.;
Parks, D. J.; Pouliot, J. J.; Price, D. J.; Rai, R.; Seal, J. W. III,
Schmitz, U.; Tai, V. W. F.; Thomson, M.; Xie, M.; Xiong, Z. Z.;
Peat, A. J. ACS Med. Chem. Lett. 2013, 3, 565–569; (b) Bode, M.
L.; Gravestock, D.; Moleele, S. S.; van der Westhuyzen, C. W.;
Pelly, S. C.; Steenkamp, P. A.; Hoppe, H. C.; Khan, T.; Nkabinde,
L. A. Bioorg. Med. Chem. 2011, 19, 4227–4237; (c) Hamdouchi,
C.; de Blas, J.; del Prado, M.; Gruber, J.; Heinz, B. A.; Vance, L.
J. Med. Chem. 1999, 42, 50–59; (d) Shukla, N. M.; Salunke, D.
B.; Yoo, E.; Mutz, C. A.; Balakrishna, R.; David, S. A. Bioorg.
Med. Chem. 2012, 20, 5850–5863.
(a) Hieke, M.; Rödl, C. B.; Wisniewska, J. M.; Buscató, E. l.;
Stark, H.; Schubert-Zsilavecz, M.; Steinhilber, D.; Hofmann, B.;
Proschak, E. Bioorg. Med. Chem. Lett. 2012, 22, 1969–1975; (b)
Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Imai, K.;
Inamura, N.; Asano, M.; Hatori, C.; Katayama, A.; Oku, T.;
Tanaka, H. J. Med. Chem. 1998, 41, 564–578.
dissolved in dichloromethane and dried over sodium sulfate. The
aqueous filtrate was extracted with dichloromethane. The
combined organic layers were washed with brine, dried over
sodium sulfate, filtered and concentrated under vacuum. The crude
product was purified by silica gel chromatography using ethyl
acetate/petroleum ether (4/6) as eluent to afford 2-
chloroimidazo[1,2-a]pyridine as a white powder (20.0 g, 88%
yield). mp 76–77 °C; 1H NMR (400MHz, DMSO-d6) 8.53 (d, 3J
= 6.8 Hz, 1 H), 8.08 (s, 1 H), 7.56 (d, 3J = 9.0 Hz, 1 H), 7.35 (ddd,
3J = 9.0 Hz, 3J = 6.8 Hz, 4J = 1.2 Hz, 1 H), 7.02 (dd, 3J = 3J’ = 6.8
Hz, 1 H); 13C NMR (100 MHz, DMSO-d6) 143.22, 133.94,
126.78, 125.86, 116.20, 113.08, 109.12; IR (KBr) 3106, 1509,
1484, 744 cm-1; MS (ESI) m/z (%): 152.9 (100) [M+H]+, 155.0
(40) [M+H+2]+. 2-Chloroimidazo[1,2-a]pyridine (18.0 g, 118
mmol) was slowly added to concentrated sulfuric acid (178 mL)
cooled to – 5 °C keeping the temperature above 5 °C. To the
solution was added nitric acid (18 mL), keeping the temperature
above 5 °C too. At the end of the addition, the mixture was
allowed to reach room temperature and then stirred for 3.5 h. The
mixture was poured onto ice and the formed precipitate was
collected by filtration and dissolved in dichloromethane. The
organic layer was dried over sodium sulfate, filtered and
concentrated under vacuum to give 2-chloro-3-nitroimidazo[1,2-
a]pyridine 1 as a yellow powder (18.9 g, 81% yield). mp 175–176
°C; 1H NMR (400MHz, DMSO-d6) 9.39 (d, 3J = 7.2 Hz, 1 H),
7.97–7.90 (m, H7, 2 H), 7.57 (ddd, 3J = 8.4 Hz, 3J = 7.2 Hz, 4J =
1.6 Hz, 1 H); 13C NMR (100 MHz, DMSO-d6) 143.15, 138.67,
3.
4.
5.
Hanson, S. M.; Morlock, E. V.; Satyshur, K. A.; Czajkowski, C. J.
Med. Chem. 2008, 51, 7243–7252.
Trabanco, A. A.; Tresadern, G.; Macdonald, G. J.; Vega, J. A.; de
Lucas, A. I.; Matesanz, E.; Garcia, A.; Linares, M. L.; Alonso de
Diego, S. A.; Alonso, J. M.; Oehlrich, D.; Ahnaou, A.;
Drinkenburg, W.; Mackie, C.; Andrés, J. I.; Lavreysen, H.; Cid, J.
M. J. Med. Chem. 2012, 55, 2688–2701.
Kaminski, J. J.; Doweyko, A. M. J. Med. Chem. 1997, 40, 427–
436.
(a) Burchak, O. N.; Mugherli, L.; Ostuni, M.; Lacapère, J. J.;
Balakirev, M. Y. J. Am. Chem. Soc. 2011, 133, 10058–10061; (b)
Stasyuk, A. J.; Banasiewicz, M.; Cyrański, M. K.; Gryko, D. T. J.
Org. Chem. 2012, 77, 5552–5558.
6.
7.
132.84, 128.66, 127.50, 117.75, 117.38; IR (KBr) 3114, 1507,
1450, 1477, 1347, 768, 749 cm-1; MS (ESI) m/z (%): 197.9 (100)
[M+H]+, 199.9 (35) [M+H+2]+.
17. Recently, 3-nitro-2-phenylimidazo[1,2-a]pyridine was obtained
from 2-aminopyridine and (E)-(2-nitrovinyl)benzene: Yan, R.-L.;
Yan, H.; Ma, C.; Ren, Z.-Y.; Gao, X.-A.; Huang, G.-S.; Liang, Y.-
M. J. Org. Chem. 2012, 77, 2024–2028.
18. Hand, E. S.; Paudler, W. W. J. Org. Chem. 1978, 43, 658–663.
19. General procedure for Suzuki coupling: 2-(4-fluorophenyl)-3-
nitroimidazo[1,2-a]pyridine (3c). To a solution of 2-chloro-3-
nitroimidazo[1,2-a]pyridine (100 mg, 0.5 mmol) in a mixture
dimethoxyethane–water (12 mL, 2:1) was added 4-
8.
9.
Marhadour, S.; Marchand, P.; Pagniez, F.; Bazin, M.-A.; Picot, C.;
Lozach, O.; Ruchaud, S.; Antoine, M.; Meijer, L.; Rachidi, N.; Le
Pape, P. Eur. J. Med. Chem. 2012, 58, 543–556.
(a) Hand, E. S.; Paudler, W. W. J. Org. Chem. 1976, 41, 3549–
3556; (b) Leonardi, A.; Motta, G.; Riva, C.; Poggesi, E.; Graziani,
D. PCT Int. Appl. 2010089119, 2010; Chem. Abstr. 2010, 153,
311117; (c) Leonardi, A.; Motta, G.; Riva, C.; Poggesi, E.;
Graziani, D.; Longhi, M. M. PCT Int. Appl. 2009015897, 2009;
Chem. Abstr. 2009, 150, 168179.
fluorophenylboronic acid (85 mg, 0.6 mmol), sodium carbonate
(134 m g, 1.3 mmol) and Pd(PPh3)4 (5% mol, 30 mg). The
suspension was then purged with argon through the septum inlet
for 5 min and heated at reflux for 3 h. After cooling, the resulting
mixture was diluted with dichloromethane. Water was added and
the organic layer was extracted with dichloromethane. The
combined organic layers were washed with water, dried over
sodium sulfate, filtered and concentrated under vacuum. The crude
product was purified by silica gel chromatography using
dichloromethane/ethanol (99:1) as eluent to afford 2-(4-
fluorophenyl)-3-nitroimidazo[1,2-a]pyridine 3c as a yellow
powder (126 mg, 97% yield). mp 227–228 °C; 1H NMR
(400MHz, DMSO-d6) 7.40 (dd, 3J = 8.8 Hz, 3J = 8.8 Hz, 2 H),
7.53 (ddd, 3J = 7.0 Hz, 3J = 7.0 Hz, 4J = 1.2 Hz, 1 H), 7.87–7.91
(m, 1 H), 7.94–8.02 (m, 3 H), 9.47 (dd, 3J = 7.0 Hz, 4J = 1.2 Hz, 1
H); 13C NMR (100 MHz, DMSO-d6) 114.96 (d, 2JC-F = 21 Hz, 2
C), 117.17, 117.78, 128.44, 128.67 (d, 4JC-F = 3 Hz), 128.86,
131.96, 132.34 (d, 3JC-F = 9 Hz, 2 C), 144.63, 148.10, 162.95 (d,
1JC-F = 246 Hz); IR (KBr) 3032, 1605, 1481, 1366, 1327, 1211,
833, 756 cm-1; MS (ESI) m/z (%): 258.1 (100) [M+H]+; Anal.
Calcd for C13H8FN3O2: C 60.70; H 3.13; N 16.34. Found: C 61.03;
H 3.05; N 16.68%.
10. Tran, V. C.; Dao, D. T.; Tran, V. L.; Van Sung, T. Tap Chi Hoa
Hoc 2007, 45, 781–784.
11. Ohta, K.; Minami, K.; Yoshikawa, H.; Ishida, Y. Biosci.
Biotechnol. Biochem. 1993, 57, 1844–1848.
12. Newton, C. G.; Ollis, W. D.; Wright, D. E. J. Chem. Soc., Perkin
Trans. 1 1984, 1, 69–73.
13. (a) Désaubry, L.; Wermuth, C. G.; Bourguignon, J.-J. Tetrahedron
Lett. 1995, 36, 4249–4252; (b) Salomé, C.; Schmitt, M.;
Bourguignon, J.-J. Tetrahedron Lett. 2009, 50, 3798–3800.
14. (a) Groebke, K.; Weber, L.; Mehlin, F. Synlett 1998, 661–663; (b)
Blackburn, C.; Guan, B.; Fleming, P.; Shiosaki, K.; Tsai, S.
Tetrahedron Lett. 1998, 39, 3635–3638; (c) Bienaymé, H.;
Bouzid, K. Angew. Chem. Int. Ed. 1998, 37, 2234–2237.
15. Marhadour, S.; Bazin, M.-A.; Marchand, P. Tetrahedron Lett.
2012, 53, 297–300.
16. Three-step synthesis of 2-chloro-3-nitroimidazo[1,2-a]pyridine 1.
To chloroacetic acid (19.0 g, 201 mmol) in water (31 mL) was
added triethylamine (32 mL, 232 mmol) dropwise at room
temperature. After stirring for 10 min, 2-aminopyridine (23.0 g,
244 mmol) was added and the resulting brown solution was
warmed to 90 °C for 5 h. After cooling to room temperature,
ethanol (21 mL) was added and the suspension was stirred at 5 °C
for 2 h. The precipitate was collected by filtration and washed
with cold ethanol to afford (2-iminopyridin-1(2H)-yl)acetic acid
as a white powder (26.4 g, 71% yield). mp 257–258 °C; 1H NMR
(400MHz, DMSO-d6) 7.35 (d, 3J = 6.4 Hz, 1 H), 6.90 (ddd, 3J =
8.6 Hz, 3J = 6.4 Hz, 4J = 2.0 Hz, 1 H), 6.42 (d, 3J = 8.6 Hz, 1 H),
5.78 (dd, 3J = 3J’ = 6.4 Hz, 1 H), 3.32 (s, 2 H); 13C NMR (100
MHz, DMSO-d6) 158.34, 139.38, 135.32, 119.07, 103.36, 38.76;
20. Blackburn, C.; Guan, B. Tetrahedron Lett. 2000, 41, 1495–1500.
21. General procedure for the synthesis of ureas 6a-f: 1-ethyl-3-(2-
phenylimidazo[1,2-a]pyridin-3-yl)urea (6a). To a solution of 2-
phenylimidazo[1,2-a]pyridin-3-amine 4 (100 mg, 0.48 mmol, 1
equiv.) in dimethylformamide (2 mL) was added ethyl isocyanate
(75 L, 0.96 mmol, 2 equiv.). The suspension was heated at 80 °C
for 16 h. After cooling, the solvent was removed under reduced
pressure. The crude product was purified by silica gel
IR (KBr) 3246, 3041, 1701, 1627, 1586 cm-1; MS (ESI) m/z (%):
153.0 (100) [M+H]+. To (2-iminopyridin-1(2H)-yl)acetic acid
(23.0 g, 151 mmol) in toluene (200 mL) was added dropwise
phosphorus oxychloride (42.0 mL, 453 mmol) at room
temperature. The reaction mixture was refluxed for 16 h and
cooled to room temperature. Cold water (500 mL) was added and
the solution was stirred for 15 min. The layers were separated. In
an ice bath, the aqueous layer was neutralized with 10% sodium
hydroxide aqueous solution. The precipitate was filtered,
chromatography using EtOAc/petroleum ether/ (2:3) as eluent to
afford 1-ethyl-3-(2-phenylimidazo[1,2-a]pyridin-3-yl)urea 6a as a
beige powder (74 mg, 55% yield). mp 190–191 °C; 1H NMR
(400MHz, DMSO-d6) 3.18–2.99 (m, 5 H), 6.99 (dd, 3J = 3J’ = 6.8
Hz, 1 H), 7.41–7.36 (m, 2 H), 7.49 (dd, 3J = 3J’ = 7.4 Hz, 2 H),
7.70 (d, 3J = 9.2 Hz, 1 H), 7.85 (d, 3J = 7.4 Hz, 2 H), 8.05 (d, 3J =
6.8 Hz, 1 H), 8.32–8.29 (m, 2 H); 13C NMR (100 MHz, DMSO-d6)
14.96, 35.03, 112.85, 114.65, 117.31, 123.30, 125.80, 126.26 (2